-
公开(公告)号：US08476948B2
公开(公告)日：2013-07-02
申请号：US12614047
申请日：2009-11-06
Applicant: Rajeev Jain
Inventor： Rajeev Jain
IPC: H03K3/00
CPC classification number: H03K3/3565
Abstract: A Schmitt trigger circuit includes a first inverter having an input coupled to an input terminal; a second inverter having an input coupled to the input terminal; a first transistor having a source coupled to VDD, a drain coupled to an output of the first inverter, and a gate coupled to an output terminal; a second transistor having a source coupled to ground, a drain coupled to an output of the second inverter, and a gate coupled to the output terminal; a third transistor having a source coupled to VDD, a drain coupled to the output terminal, and a gate coupled to the output of the first inverter; and a fourth transistor having a source coupled to ground, a drain coupled to the output terminal, and a gate coupled to the output of the second inverter.
Abstract translation: 施密特触发电路包括具有耦合到输入端的输入的第一反相器; 第二反相器，其具有耦合到所述输入端子的输入; 具有耦合到VDD的源极的第一晶体管，耦合到第一反相器的输出端的漏极和耦合到输出端子的栅极; 第二晶体管，其具有耦合到地的源极，耦合到第二反相器的输出的漏极和耦合到输出端子的栅极; 具有耦合到VDD的源极的第三晶体管，耦合到输出端子的漏极和耦合到第一反相器的输出端的栅极; 以及第四晶体管，其具有耦合到地的源极，耦合到输出端子的漏极和耦合到第二反相器的输出端的栅极。
-
公开(公告)号：US07927627B2
公开(公告)日：2011-04-19
申请号：US11802542
申请日：2007-05-23
Applicant: Tuula Ryde , Evan E. Gustow , Stephen B. Ruddy , Rajeev Jain , Rakesh Patel , Michael John Wilkins
Inventor： Tuula Ryde , Evan E. Gustow , Stephen B. Ruddy , Rajeev Jain , Rakesh Patel , Michael John Wilkins
IPC: A61K9/14 , A61K31/235 , A61K9/50 , A61P3/04 , A61P43/00 , A61P9/00 , C07C69/767 , C13K13/00
CPC classification number: A61K31/19 , A61K9/145 , A61K9/146 , A61K9/2077 , A61K31/14 , A61K31/216 , A61K45/06 , Y10T428/29 , A61K2300/00
Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
-
23.发明授权公开(公告)号：US07695739B2
公开(公告)日：2010-04-13
申请号：US11650412
申请日：2007-01-08
Applicant: Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
Inventor： Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
CPC classification number: A61K9/1635 , A61K9/0095 , A61K9/145 , A61K9/146 , A61K9/1623
Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
Abstract translation: 公开了用于评价水溶性差的活性剂的剂型的体内再分散性的体外方法。 该方法利用代表体内人体生理条件的介质。
-
公开(公告)号：US20080095851A1
公开(公告)日：2008-04-24
申请号：US11802567
申请日：2007-05-23
Applicant: Tuula Ryde , Evan Gustow , Stephen Ruddy , Rajeev Jain , Rakesh Patel , Michael Wilkins
Inventor： Tuula Ryde , Evan Gustow , Stephen Ruddy , Rajeev Jain , Rakesh Patel , Michael Wilkins
IPC: A61K9/14 , A61K31/216 , A61P3/00
CPC classification number: A61K31/19 , A61K9/145 , A61K9/146 , A61K9/2077 , A61K31/14 , A61K31/216 , A61K45/06 , Y10T428/29 , A61K2300/00
Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
-
25.发明申请In vitro methods for evaluating the in vivo effectivness of dosage forms of microparticulate or nanoparticulate active agent compositions 有权用于评估微粒或纳米颗粒活性剂组合物的剂型的体内有效性的体外方法公开(公告)号：US20070110776A1
公开(公告)日：2007-05-17
申请号：US11650412
申请日：2007-01-08
Applicant: Eugene Cooper , John Bullock , John Chippari , John Schaefer , Rakesh Patel , Rajeev Jain , Joost Strasters , Niels Ryde , Stephen Ruddy
Inventor： Eugene Cooper , John Bullock , John Chippari , John Schaefer , Rakesh Patel , Rajeev Jain , Joost Strasters , Niels Ryde , Stephen Ruddy
IPC: A61K9/00
CPC classification number: A61K9/1635 , A61K9/0095 , A61K9/145 , A61K9/146 , A61K9/1623
Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
Abstract translation: 公开了用于评价水溶性差的活性剂的剂型的体内再分散性的体外方法。 该方法利用代表体内人体生理条件的介质。
-
Patent Agency Ranking
26.发明申请NANOPARTICULATE COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE INHIBITORS 有权活化蛋白（MAP）激酶抑制剂的纳米颗粒组合物公开(公告)号：US20060193920A1
公开(公告)日：2006-08-31
申请号：US11275069
申请日：2005-12-07
Applicant: H. Bosch , Greta Cary , Douglas Hovey , Rajeev Jain , Laura Kline , Elaine Merisko-Liversidge , Kevin Ostrander
Inventor： H. Bosch , Greta Cary , Douglas Hovey , Rajeev Jain , Laura Kline , Elaine Merisko-Liversidge , Kevin Ostrander
IPC: A61K48/00 , A61K38/17 , A61K31/66 , A61K31/525 , A61K31/522 , A61K31/385 , A61K31/557 , A61K36/82 , A61K36/886 , A61K36/328
CPC classification number: A61K38/1709 , A61K9/0075 , A61K9/146 , A61K9/2022 , A61K31/385 , A61K31/522 , A61K31/525 , A61K31/557 , A61K31/66
Abstract: Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
Abstract translation: 描述了包含至少一种难溶性MAP激酶抑制剂和至少一种表面稳定剂的纳米颗粒组合物。 纳米颗粒组合物具有小于约2000nm的平均粒度。 本发明还描述了制备和使用这些组合物的方法。
-
27.发明申请Methods for making pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability 审中-公开制备包含具有改善的分散性，悬浮性或润湿性的微粒的药物制剂的方法公开(公告)号：US20050079138A1
公开(公告)日：2005-04-14
申请号：US10955261
申请日：2004-09-30
Applicant: Donald Chickering , Shaina Reese , Sridhar Narasimhan , Julie Straub , Howard Bernstein , David Altreuter , Eric Huang , Luis Brito , Rajeev Jain
Inventor： Donald Chickering , Shaina Reese , Sridhar Narasimhan , Julie Straub , Howard Bernstein , David Altreuter , Eric Huang , Luis Brito , Rajeev Jain
CPC classification number: B01D1/18 , A61K9/0075 , A61K9/145 , A61K9/1647 , A61K9/1694 , B01J2/04
Abstract: Methods are provided for making a dry powder blend pharmaceutical formulation, comprising the steps of: (a) providing microparticles which comprise a pharmaceutical agent; (b) blending the microparticles with at least one excipient in the form of particles to form a powder blend; and (c) jet milling the powder blend to form a dry powder blend pharmaceutical formulation having improved dispersibility, suspendability, or wettability as compared to the microparticles of step (a) or the powder blend of step (b). The method can further include dispersing the dry powder blend pharmaceutical formulation in a liquid pharmaceutically acceptable vehicle to make an formulation suitable for injection. Alternatively, the method can further include processing the dry powder blend pharmaceutical formulation into a solid oral dosage form. In one embodiment, the microparticles of step (a) are formed by a solvent precipitation or crystallization process.
Abstract translation: 提供用于制备干粉混合药物制剂的方法，包括以下步骤：（a）提供包含药剂的微粒; （b）将微粒与颗粒形式的至少一种赋形剂混合以形成粉末混合物; 和（c）与步骤（a）的微粒或步骤（b）的粉末混合物相比，喷粉研磨粉末混合物以形成具有改善的分散性，悬浮性或润湿性的干粉混合物药物制剂。 该方法还可以包括将干粉混合物药物制剂分散在液体药学上可接受的载体中以制备适于注射的制剂。 或者，该方法还可以包括将干粉混合药物制剂加工成固体口服剂型。 在一个实施方案中，步骤（a）的微粒通过溶剂沉淀或结晶过程形成。
-
28.发明授权公开(公告)号：US08309136B2
公开(公告)日：2012-11-13
申请号：US12729018
申请日：2010-03-22
Applicant: Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
Inventor： Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
CPC classification number: A61K9/1635 , A61K9/0095 , A61K9/145 , A61K9/146 , A61K9/1623
Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
Abstract translation: 公开了用于评价水溶性差的活性剂的剂型的体内再分散性的体外方法。 该方法利用代表体内人体生理条件的介质。
-
公开(公告)号：US20100322853A1
公开(公告)日：2010-12-23
申请号：US12870745
申请日：2010-08-27
Applicant: Elaine Merisko-Liversidge , H. William Bosch , Greta G. Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
Inventor： Elaine Merisko-Liversidge , H. William Bosch , Greta G. Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
IPC: A61K31/565 , A61K9/00 , A61K9/20 , A61K9/48 , A61K38/16 , A61K31/7052 , A61K49/00 , A61K36/00 , A61K36/886 , A61K36/82 , A61K36/55 , A61K35/60 , A61K35/00 , A61K39/00 , A61P35/00 , A61P9/00 , A61P3/04
CPC classification number: A61K31/00 , A61K9/145 , A61K9/146 , A61K9/148 , A61K31/565
Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
-
30.发明申请IN VITRO METHODS FOR EVALUATING THE IN VIVO EFFECTIVENESS OF DOSAGE FORMS OF MICROPARTICULATE OR NANOPARTICULATE ACTIVE AGENT COMPOSITIONS 有权用于评估微量元素或纳米颗粒活性剂组合物剂量形式的生物活性的体外方法公开(公告)号：US20100178648A1
公开(公告)日：2010-07-15
申请号：US12729018
申请日：2010-03-22
Applicant: Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
Inventor： Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
IPC: C12Q1/00
CPC classification number: A61K9/1635 , A61K9/0095 , A61K9/145 , A61K9/146 , A61K9/1623
Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
Abstract translation: 公开了用于评价水溶性差的活性剂的剂型的体内再分散性的体外方法。 该方法利用代表体内人体生理条件的介质。
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.026 seconds)
